1. Home
  2. CTNM vs BNED Comparison

CTNM vs BNED Comparison

Compare CTNM & BNED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • BNED
  • Stock Information
  • Founded
  • CTNM 2009
  • BNED 1965
  • Country
  • CTNM United States
  • BNED United States
  • Employees
  • CTNM N/A
  • BNED N/A
  • Industry
  • CTNM
  • BNED Other Specialty Stores
  • Sector
  • CTNM
  • BNED Consumer Discretionary
  • Exchange
  • CTNM Nasdaq
  • BNED Nasdaq
  • Market Cap
  • CTNM 248.7M
  • BNED 295.2M
  • IPO Year
  • CTNM 2024
  • BNED N/A
  • Fundamental
  • Price
  • CTNM $12.40
  • BNED $9.10
  • Analyst Decision
  • CTNM Strong Buy
  • BNED
  • Analyst Count
  • CTNM 4
  • BNED 0
  • Target Price
  • CTNM $22.75
  • BNED N/A
  • AVG Volume (30 Days)
  • CTNM 246.0K
  • BNED 306.6K
  • Earning Date
  • CTNM 11-05-2025
  • BNED 09-12-2025
  • Dividend Yield
  • CTNM N/A
  • BNED N/A
  • EPS Growth
  • CTNM N/A
  • BNED N/A
  • EPS
  • CTNM N/A
  • BNED N/A
  • Revenue
  • CTNM N/A
  • BNED $1,567,800,000.00
  • Revenue This Year
  • CTNM N/A
  • BNED $2.74
  • Revenue Next Year
  • CTNM N/A
  • BNED N/A
  • P/E Ratio
  • CTNM N/A
  • BNED N/A
  • Revenue Growth
  • CTNM N/A
  • BNED N/A
  • 52 Week Low
  • CTNM $3.35
  • BNED $7.90
  • 52 Week High
  • CTNM $20.30
  • BNED $14.41
  • Technical
  • Relative Strength Index (RSI)
  • CTNM 69.65
  • BNED 56.41
  • Support Level
  • CTNM $11.46
  • BNED $8.10
  • Resistance Level
  • CTNM $13.09
  • BNED $8.73
  • Average True Range (ATR)
  • CTNM 1.02
  • BNED 0.37
  • MACD
  • CTNM -0.07
  • BNED 0.11
  • Stochastic Oscillator
  • CTNM 74.89
  • BNED 87.77

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About BNED Barnes & Noble Education Inc

Barnes & Noble Education Inc is an operator of bookstores in college and university campuses across the United States. The company is also engaged in providing digital education services. It operates in three reportable segments that include Retail offers existing and prospective clients the flexibility of physical, virtual, or custom store solutions, and wholesale is comprised of the wholesale and virtual retail fulfillment, and support operations of the MBS subsidiary, also Corporate Services represent unallocated shared-service costs which include corporate level expenses and other governance functions, including executive functions, such as accounting, legal, treasury, information technology, and human resources. It earns majority of the revenue from Retail segment.

Share on Social Networks: